Flemming Brandt Sørensen

Flemming Brandt Sørensen

Auto-generated profile, based on publicly available information

Flemming Brandt Sørensen

Danish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1988 in APMIS
Verified
Journal Article
Closed access
PDF file
HGH. J. G. Gundersen
H. J. G. Gundersen
TBT. F. Bendtsen
T. F. Bendtsen
LKL. Korbo
L. Korbo
NMN. Marcussen
N. Marcussen
AMA. Møller
A. Møller
MWM. J. West
M. J. West

1 July 1988 in APMIS
Verified
Journal Article
Closed access
PDF file
HGH. J. G. Gundersen
H. J. G. Gundersen
PBP. Bagger
P. Bagger
TBT. F. Bendtsen
T. F. Bendtsen
SES. M. Evans
S. M. Evans
LKL. Korbo
L. Korbo
MWM. J. West
M. J. West

20 March 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MKMarianne Kyndi
Marianne Kyndi
FSFlemming B Sørensen
Flemming B Sørensen
HKHelle Knudsen
Helle Knudsen
MOMarie Overgaard
Marie Overgaard
HNHanne Melgaard Nielsen
Hanne Melgaard Nielsen
DGDanish Breast Cancer Cooperative Group
Danish Breast Cancer Cooperative Group
Purpose To examine the importance of estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER-2), and constructed subtypes in a large study randomly assigning patients to receive or not receive postmastectomy radiotherapy (PMRT). Patients and Methods The present analysis included 1,000 of the 3,083 high-risk breast cancer patients randomly assigned to PMRT in the Danish Breast Cancer Cooperative Group (DBCG) protocol 82 trials b and c. Tissue microarray sections were stained for ER, PgR, and HER-2. Median follow-up time for patients alive was 17 years. End points were locoregional recurrence as isolated first event, distant metastases, and overall survival. For statistical analyses four subgroups were constructed from hormonal receptors (Rec). Rec+ was defined as ER+ and/or PgR+. Rec–as both ER–and PgR–. The four subgroups were Rec+/HER-2–, Rec+/HER-2+, Rec–/HER-2–(triple negative), and Rec–/HER-2+. Results A significantly improved overall survival after PMRT was seen only among patients characterized by good prognostic markers such as hormonal receptor–positive and HER-2− patients (including the two Rec+ subtypes). No significant overall survival improvement after PMRT was found among patients with an a priori poor prognosis, the hormonal receptor–negative and HER-2+ patients, and in particular the Rec–/HER-2+ subtype. Furthermore, comparing hazard ratios and 95% CIs, significantly smaller improvements in locoregional recurrence control after PMRT were found for ER–and PgR–tumors compared with the ER+ and PgR+ tumors (P = .003 and .04, respectively), and for the triple-negative (P = .02), and the Rec–/HER-2+ subtypes (P = .003) compared with the Rec+/HER-2–subtype. Conclusion Hormonal receptor status, HER-2, and the constructed subtypes may be predictive of locoregional recurrence and survival after postmastectomy radiotherapy.

20 July 2018 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
GPG. W. van Pelt
G. W. van Pelt
SKS. Kjær-Frifeldt
S. Kjær-Frifeldt
JKJ. H. J. M. van Krieken
J. H. J. M. van Krieken
RDR. Al Dieri
R. Al Dieri
HMH. Morreau
H. Morreau
WMWilma Mesker
Wilma Mesker
The tumor-stroma ratio (TSR) has been reported as a strong, independent prognostic parameter in colon cancer as well as in other epithelial cancer types, and may be implemented to routine pathology diagnostics. The TSR is an easy technique, based on routine hematoxylin and eosin stained histological sections, estimating the amount of stroma present in the primary tumor. It links tumors with high stromal content to poor prognosis. The analysis time is less than 2 min with a low inter-observer variation. Scoring of the TSR has been validated in a number of independent international studies. In this manuscript, we provide a detailed technical description of estimating the TSR in colon cancer, including examples, pitfalls, and recommendations.

1 April 2006 in Cancer Research
Verified
Journal Article
Closed access
MAMads Aaboe
Mads Aaboe
KBKarin Birkenkamp-Demtroder
Karin Birkenkamp-Demtroder
CWCarsten Wiuf
Carsten Wiuf
FSFlemming Brandt Sørensen
Flemming Brandt Sørensen
TTThomas Thykjaer
Thomas Thykjaer
TØTorben Ørntoft
Torben Ørntoft
The human transcription factor SOX4 was 5-fold up-regulated in bladder tumors compared with normal tissue based on whole-genome expression profiling of 166 clinical bladder tumor samples and 27 normal urothelium samples. Using a SOX4-specific antibody, we found that the cancer cells expressed the SOX4 protein and, thus, did an evaluation of SOX4 protein expression in 2,360 bladder tumors using a tissue microarray with clinical annotation. We found a correlation (P < 0.05) between strong SOX4 expression and increased patient survival. When overexpressed in the bladder cell line HU609, SOX4 strongly impaired cell viability and promoted apoptosis. To characterize downstream target genes and SOX4-induced pathways, we used a time-course global expression study of the overexpressed SOX4. Analysis of the microarray data showed 130 novel SOX4-related genes, some involved in signal transduction (MAP2K5), angiogenesis (NRP2), and cell cycle arrest (PIK3R3) and others with unknown functions (CGI-62). Among the genes regulated by SOX4, 25 contained at least one SOX4-binding motif in the promoter sequence, suggesting a direct binding of SOX4. The gene set identified in vitro was analyzed in the clinical bladder material and a small subset of the genes showed a high correlation to SOX4 expression. The present data suggest a role of SOX4 in the bladder cancer disease. (Cancer Res 2006; 66(7): 3434-42)

13 January 2015 in British Journal of Cancer
Verified
Journal Article
Open access
THTorben Hansen
Torben Hansen
ACA L Carlsen
A L Carlsen
NHN H H Heegaard
N H H Heegaard
FSF B Sørensen
F B Sørensen
Anders JakobsenAnders Jakobsen
Anders Jakobsen
This study investigated the predictive value of circulating microRNA-126 (cir-miRNA-126) in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy combined with bevacizumab. The study included 68 patients. Blood samples (plasma) were collected before the treatment initiation, at the first clinical evaluation after 3 weeks and at progression. Levels of cir-miRNA-126 were determined by qRT-PCR after purification of total RNA from plasma. Primary clinical end points were response rates evaluated according to the Response Evaluation Criteria In Solid Tumours (RECIST) and progression-free survival (PFS). Changes in circulating miRNA-126 during treatment were predictive of tumour response. Non-responding patients had a median increase in cir-miRNA-126 of 0.244 (95% confidence interval (CI), 0.050-0.565) compared with a median decrease of -0.374 (95% CI, -0.472 to -0.111) in the responding patients, P=0.002. A significant positive correlation was demonstrated by comparing the changes in tumour size with the changes in cir-miRNA-126, r=0.48, P=0.0001. Grouping the patients according to the changes in cir-miRNA-126 disclosed a borderline significant separation of the groups in the PFS analysis favouring patients with decreasing miRNA-126 levels, hazard ratio (HR) 0.60 (95% CI, 0.33-1.09), P=0.07. The present results indicate that changes in cir-miRNA-126 during treatment are related to the response to chemotherapy and bevacizumab in patients with mCRC, thus representing a possible biomarker for the resistance to anti-angiogenic containing treatments.